Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Multicenter Single-Arm Observational Registry Study to Assess the Safety and Efficacy of EXCEL-II With Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery (CREDIT-III Trial)

Next Previous
X
Search
Trial Profile

A Prospective Multicenter Single-Arm Observational Registry Study to Assess the Safety and Efficacy of EXCEL-II With Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery (CREDIT-III Trial)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms CREDIT-III
  • Sponsors JW Medical Systems

    • Most Recent Events

    • 25 Apr 2023 Status changed from recruiting to completed.
    • 01 Mar 2017 Results of a pooled analysis assessing objective performance criteria in patients from two clinical studies (CREDIT-II and CREDIT-III; n=833), published in the Catheterization and Cardiovascular Interventions
    • 11 Mar 2015 To date, 637 patients have been enrolled, according to a Biosensors International Group media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top